Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Public ClinicalTrials.gov record NCT00263588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during the course of the study.
Study identification
- NCT ID
- NCT00263588
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 242 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2, 2005 (Actual)
- Primary completion
- Sep 25, 2007 (Actual)
- Completion
- Mar 15, 2018 (Actual)
- Last update posted
- Dec 12, 2019
2005 – 2018
United States locations
- U.S. sites
- 28
- U.S. states
- 18
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | San Francisco | California | 94115 | — |
| Novartis Investigative Site | Vallejo | California | 94589 | — |
| Novartis Investigative Site | Denver | Colorado | 80220 | — |
| Novartis Investigative Site | Washington D.C. | District of Columbia | 20007 | — |
| Novartis Investigative Site | Boca Raton | Florida | 33428 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32224 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46202 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46227 | — |
| Novartis Investigative Site | Sioux City | Iowa | 51101-1733 | — |
| Novartis Investigative Site | Kansas City | Kansas | 66160 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02115 | — |
| Novartis Investigative Site | Ann Arbor | Michigan | 48109 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55455 | — |
| Novartis Investigative Site | St Louis | Missouri | 63110-1093 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87106 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87108 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87131-0001 | — |
| Novartis Investigative Site | Santa Fe | New Mexico | 87505 | — |
| Novartis Investigative Site | New York | New York | 10021 | — |
| Novartis Investigative Site | Chapel Hill | North Carolina | 27599 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Novartis Investigative Site | Pittsburgh | Pennsylvania | 15213 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | Tyler | Texas | 75702 | — |
| Novartis Investigative Site | Seattle | Washington | 98109 | — |
| Novartis Investigative Site | Yakima | Washington | 98902 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00263588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2019 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00263588 live on ClinicalTrials.gov.